A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.

Inclusion Criteria: * cMET dysregulated advanced solid tumor * At least one measurable lesion as defined by RECIST 1.1 * Recovered from all toxicities related to prior anti-cancer therapies to grade ≤ 1 * Adequate organ function * ECOG performance status (PS) ≤ 1 Exclusion Criteria: * Prior treatment with crizotinib or any other cMET or HGF inhibitor * Known hypersensitivity to any of the excipients of INC280 * Symptomatic central nervous system (CNS) metastases who are neurologically unstable * Presence or history of a malignant disease other than the study related cancer * Clinically significant, uncontrolled heart diseases * Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities * Major surgery within 4 weeks prior to starting INC280 * Impairment of GI function * Patients receiving unstable or increasing doses of corticosteroids * Patients receiving treatment with any enzyme-inducing anticonvulsant * Pregnant or nursing (lactating) women Other protocol-related inclusion/exclusion criteria may apply